INDV
IndiviorDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Bull case: successful continuation of US commercial momentum and improved payer coverage drive >25% upside within 6–12 months as revenue/margin mix improves and valuation multiple re-rates.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Bear case: regulatory or litigation setbacks, or rapid generic entry, drive material downside (>25%) as revenue shocks and multiple compression occur.
Momentum
48
Value
54
Sentiment
32
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $33.36 · Bull $45.66 · Bear $26.34
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $50.83
Why
Momentum48 · Δ7d -20.3
Value54 · Δ7d -0.2
Sentiment32 · Δ7d -2.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
48
26% active weight
Current posture
7d trendSoftening
Δ7d
-20.3
Δ21d
-34.9
Value
54
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+0.1
Sentiment
32
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
+0.9
Why this grade
Composite grade D. Momentum 48.5 / Value 53.9 / Sentiment 31.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$4.94B
Beta
1.14
Shares Out
124.85M
P/E (TTM)
37.8
P/S (TTM)
3.84
P/FCF (TTM)
37.72
Rev YoY
+19.2%
EPS YoY
+83.5%
Gross Margin
+83.1%
Op Margin
+18.7%
Net Debt
$156M
Current Ratio
0.86
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology